ChronoScale Holdings Corp
No SEC Form 4 filings for $CHRN in the last 30 days.
See all $CHRN insider activity →ChronoScale (CHRN) and Ekso Bionics amended a $2.0M term loan with B. Riley, extending its maturity to November 2026 and allowing potential sale of the guarantor, preserving other terms.
ChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Effective as of September 12, 2026, ChronoScale Intermediate, LLC, a Nevada limited liability company (f/k/a Ekso Bionics Holdings, Inc. and ChronoScale Corporation, the “Borrower”) and Ekso Bionics, Inc., a Delaware corporatio
ChronoScale plans a 50 MW AI infrastructure deployment with Microsoft using NVIDIA systems. The project's funding, execution, and terms are key uncertainties. Microsoft benefits from added AI compute capacity. ChronoScale's shares may be diluted if debt is unavailable or expensive. NVIDIA supply and schedules are critical for the project's success. Microsoft's AI buildout faces return-on-capital challenges. ChronoScale's short interest is 12.3% of float.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning CHRN (ChronoScale Holdings Corp). Coverage has been balanced: 0 bullish, 4 neutral, and 0 bearish.
Recent CHRN coverage spans corporate actions, technology and market movers.
Extended loan term may improve short‑term liquidity but adds longer debt exposure.
The amendment may improve liquidity but adds modest debt, likely limited price impact.
Potential upside if financing is secured; risk if funding gaps force equity dilution.
Nutanix (NTNX) reported Q4 2026 revenue of $757.08M and full-year revenue of $2.85B, with fiscal 2027 guidance of $755-765M for Q1 and $3.18-3.23B for the year. The company expanded its AI offerings with new Enterprise AI and Kubernetes releases, and partnered with ChronoScale for hybrid infrastructure AI deployments. Analysts highlight AI and cloud partnerships as key growth drivers, while noting risks like competition and revenue recognition timing.
The divestiture plan signals a strategic shift to pure AI cloud services, reducing exposure to the wearable‑robotics segment.
AlphAI scores every news story that mentions CHRN with an AI model for sentiment and relevance, and aggregates insider trades from ChronoScale Holdings Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
ChronoScale (CHRN) and Ekso Bionics amended a $2.0M term loan with B. Riley, extending its maturity to November 2026 and allowing potential sale of the guarantor, preserving other terms.
1 min readChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Effective as of September 12, 2026, ChronoScale Intermediate, LLC, a Nevada limited liability company (f/k/a Ekso Bionics Holdings, Inc. and ChronoScale Corporation, the “Borrower”) and Ekso Bionics, Inc., a Delaware corporatio
1 min readChronoScale plans a 50 MW AI infrastructure deployment with Microsoft using NVIDIA systems. The project's funding, execution, and terms are key uncertainties. Microsoft benefits from added AI compute capacity. ChronoScale's shares may be diluted if debt is unavailable or expensive. NVIDIA supply and schedules are critical for the project's success. Microsoft's AI buildout faces return-on-capital challenges. ChronoScale's short interest is 12.3% of float.
2 min readNutanix (NTNX) reported Q4 2026 revenue of $757.08M and full-year revenue of $2.85B, with fiscal 2027 guidance of $755-765M for Q1 and $3.18-3.23B for the year. The company expanded its AI offerings with new Enterprise AI and Kubernetes releases, and partnered with ChronoScale for hybrid infrastructure AI deployments. Analysts highlight AI and cloud partnerships as key growth drivers, while noting risks like competition and revenue recognition timing.
2 min readChronoScale (CHRN), formerly Ekso Bionics, plans to divest its wearable-robotics business. The company, now focused on AI computing, aims to complete the sale by August 31, though uncertainty remains. Ekso Bionics reported $12.8M revenue and $11.7M net loss in 2025. ChronoScale's stock rose 6% on a new Microsoft deal.
2 min readChronoScale (NASDAQ: CHRN) extended its partnership with Microsoft for a 50 MW AI compute deployment in North America, using NVIDIA GB300 NVL72 systems. The term was extended from two to three years, aiming to support high-density AI workloads. The deal reduces near-term renewal risk and could drive future revenue growth for ChronoScale.
2 min readChronoScale (CHRN) shares rose 7.28% in pre-market trading after announcing a 50-MW AI data center partnership with Microsoft (MSFT). The deal involves Nvidia (NVDA) systems and follows a recent agreement with Nutanix (NTNX). Despite the gain, ChronoScale's fundamentals remain weak, with a Neutral rating and $22 price target from TipRanks' AI analyst.
2 min readChronoScale Holdings (CHRN) shares rose 7% after announcing a 50-megawatt AI compute deployment with Microsoft (MSFT) in North America. The stock is trading at $22.62, up 6.96% in the session. The deployment will use NVIDIA GB300 NVL72 systems and advanced liquid-cooling infrastructure.
1 min readChronoscale Corp stock rose 7.0% to $22.64 after announcing a 50-megawatt AI compute partnership with Microsoft, using NVIDIA systems. CEO Chen highlighted the strategic importance. The Nasdaq Composite gained 0.9%, supported by Nvidia's strong earnings. Chronoscale also partnered with Nutanix, boosting its commercial pipeline.
2 min readNutanix (NTNX) partnered with ChronoScale to deliver enterprise AI infrastructure, combining Nutanix's AI software with ChronoScale's GPU platform. The alliance aims to simplify AI workload management for large enterprises. Nutanix projects $3.9B revenue and $584.9M earnings by 2029, but analysts warn of potential growth bottlenecks. The partnership could influence Nutanix's investment narrative, though risks remain.
3 min read
